01—Abstract
Summary
Summary of the 8-K filed November 12, 2024. Cited figures are marked; the original filing is the authoritative source.
Roivant Sciences Ltd. (ROIV) furnished a press release under Item 2.02 reporting financial results for the fiscal quarter ended September 30, 2024, along with a business update.
The filing states that the information is furnished, not filed, under Section 18 of the Exchange Act. For the three months ended September 30, 2024, the company reported revenue, net of $4,475 thousanda, research and development expenses of $143.1 million, and general and administrative expenses of $202.9 million, which the filing attributes in part to $79.1 million of one-time cash retention awards for senior executives. Loss from continuing operations, net of tax, was $236.8 million, or $0.25 per share, compared with $244.6 million, or $0.28 per share, a year earlier.
Non-GAAP loss from continuing operations was $218.7 millionb. Consolidated cash, cash equivalents, restricted cash and marketable securities were approximately $5.4 billion at September 30, 2024. The business update highlights clinical progress across subsidiaries, including 52-week Phase 2 NEPTUNE data for brepocitinib in non-infectious uveitis, initiation of the Phase 2 PHocus trial for mosliciguat in PH-ILD, and positive batoclimab proof-of-concept data in Graves' disease at Immunovant.
The company also closed the Dermavant sale to Organon on October 28, 2024, receiving $184 millionc in cash, with a further $75 million milestone tied to FDA approval of VTAMA in atopic dermatitis. Share repurchases totaled $106 million in the quarter and $754 million cumulatively through September 30, 2024, inclusive of the repurchase of Sumitomo's stake in April 2024. The filing lists several upcoming milestones, including topline data from Kinevant's namilumab sarcoidosis trial in the fourth quarter of calendar 2024, Immunovant's planned potentially registrational trials for IMVT-1402, topline batoclimab data in MG and CIDP by March 31, 2025, and Priovant's Phase 3 brepocitinib data in dermatomyositis in the second half of calendar 2025.
02—Key points
Key Highlights
- Quarterly loss from continuing operations, net of tax, was $236.8 million ($0.25 per share) for the three months ended September 30, 2024, versus $244.6 million ($0.28 per share) a year earlier.
- G&A expenses rose to $202.9 million from $88.6 million, including $79.1 million of one-time cash retention awards for senior executives approved in July 2024.
- R&D expenses increased to $143.1 million from $114.8 million, driven mainly by a $34.2 million increase in anti-FcRn franchise expense.
- Consolidated cash, cash equivalents, restricted cash and marketable securities totaled approximately $5.4 billion at September 30, 2024.
- Dermavant sale to Organon closed October 28, 2024: Roivant received $184 million in cash, Organon assumed $336 million of Dermavant's long-term debt and senior credit facility carrying value, and a $75 million milestone is payable upon VTAMA FDA approval in atopic dermatitis with a target action date in Q1 2025.
- Share repurchases were $106 million in the quarter and $754 million cumulatively through September 30, 2024.
- Brepocitinib 52-week NEPTUNE data in non-infectious uveitis showed potential best-in-indication efficacy sustained to one year, and Phase 3 NIU enrollment has begun.
03—Questions
Frequently Asked Questions
What were Roivant's key financial results for the quarter ended September 30, 2024?
Revenue, net was $4,475 thousand. Loss from continuing operations, net of tax, was $236.8 million, or $0.25 per basic and diluted share, compared with a loss of $244.6 million, or $0.28 per share, in the prior-year quarter. Non-GAAP loss from continuing operations was $218.7 million.
Why did general and administrative expenses increase so sharply?
G&A expenses increased $114.3 million to $202.9 million. The filing attributes $87.0 million of the increase to personnel-related expenses, including $79.1 million of one-time cash retention awards approved in July 2024 for the CEO, President and Chief Investment Officer, and President and Chief Operating Officer, and $6.6 million for a special retention bonus approved in December 2023. Share-based compensation rose $21.7 million, mainly from equity awards granted in July 2024.
What was the financial impact of the Dermavant sale to Organon?
The transaction closed on October 28, 2024. Roivant received $184 million in cash, and Organon assumed all of Dermavant's remaining long-term debt, which had a carrying value of $336 million at September 30, 2024, including the senior credit facility repaid at closing. Organon will also pay a $75 million milestone upon FDA approval of VTAMA in atopic dermatitis, and up to $950 million in commercial milestones plus tiered royalties.
What are the major upcoming catalysts disclosed in the filing?
Kinevant plans to report topline data from its Phase 2 namilumab sarcoidosis trial in Q4 2024. Immunovant expects to begin a potentially registrational Graves' disease trial by December 31, 2024, and topline batoclimab data in MG and CIDP by March 31, 2025. Priovant plans to report Phase 3 brepocitinib dermatomyositis topline data in the second half of calendar 2025.
How much capital has Roivant returned to shareholders through buybacks?
Roivant repurchased $106 million of shares during the quarter ended September 30, 2024, bringing cumulative share repurchases to $754 million through that date. The cumulative figure includes the repurchase of Sumitomo's stake in April 2024.
04—Continue